Related Experiment Video
Updated: Aug 26, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
GOT2: An Unexpected Mediator of Immunosuppression in Pancreatic Cancer
Zeribe C Nwosu1, Marina Pasca di Magliano2,3
1Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan.
Abstract:
In this issue, Abrego and colleagues describe an unexpected role for the mitochondrial enzyme glutamic-oxaloacetic transaminase (GOT2) in pancreatic cancer, whereby it acts as a nuclear fatty acid transporter binding to and activating the PPARδ nuclear receptor. In turn, the GOT2-PPARδaxis drives immunosuppression by suppressing T cell-mediated antitumor immunity. See related article by Abrego et al., p. 2414 (3).
Insights
Mitochondrial enzyme glutamic-oxaloacetic transaminase (GOT2) unexpectedly transports fatty acids to the nucleus in pancreatic cancer. This GOT2-PPARδ pathway suppresses anti-tumor immunity by inhibiting T cells.
Area of Science:
- Mitochondrial biochemistry and cancer immunology.
- Nuclear receptor signaling in oncogenesis.
Background:
- The role of mitochondrial enzymes in cancer progression is increasingly recognized.
- Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited therapeutic options.
- Nuclear receptors like PPARδ regulate gene expression involved in metabolism and inflammation.
Discussion:
- Abrego et al. reveal that glutamic-oxaloacetic transaminase (GOT2), a mitochondrial enzyme, functions as a nuclear fatty acid transporter in pancreatic cancer cells.
- GOT2 directly binds to and activates the peroxisome proliferator-activated receptor delta (PPARδ) nuclear receptor.
- This novel GOT2-PPARδ axis promotes an immunosuppressive tumor microenvironment by hindering T cell-mediated antitumor immunity.
Key Insights:
- GOT2's non-canonical function as a nuclear fatty acid transporter.
- Identification of the GOT2-PPARδ signaling axis in pancreatic cancer.
- Demonstration of GOT2-mediated immunosuppression via T cell inhibition.
Outlook:
- Targeting the GOT2-PPARδ pathway could offer a new therapeutic strategy for pancreatic cancer.
- Further investigation into GOT2's nuclear functions in other cancer types is warranted.
- Understanding this mechanism may lead to novel immunotherapeutic approaches for PDAC.
